EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma

Arina Martynchyk, Rakin Chowdhury, Eliza A Hawkes, Colm Keane

Cancers · 30.10.2023 · 15 (21) · 5217

DOI: 10.3390/cancers15215217 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.10.2023. Verfasst von Arina Martynchyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research & Wellness Centre, Austin Health, 145 Studley Rd., Heidelberg, VIC 3084, Australia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer cases globally. Despite high cure rates with standard treatment, approximately 15% of patients still experience relapsed or refractory (RR) disease, and many of these eventually die from lymphoma-related causes. Exciting new targeted agents such as anti-PD-1 agents and brentuximab vedotin have changed the therapeutic paradigm beyond chemotherapy and radiotherapy alone. Advances in understanding of the molecular biology are providing insights in the context of novel therapies. The signature histology of cHL requires the presence of scant malignant Hodgkin Reed–Sternberg cells (HRSCs) surrounded by a complex immune-rich tumour microenvironment (TME). The TME cellular composition strongly influences outcomes, yet knowledge of the precise characteristics of TME cells and their interactions with HRSCs is evolving. Novel high-throughput technologies and single-cell sequencing allow deeper analyses of the TME and mechanisms elicited by HRSCs to propagate growth and avoid immune response. In this review, we explore the evolution of knowledge on the prognostic role of immune cells within the TME and provide an up-to-date overview of emerging prognostic data on cHL from new technologies that are starting to unwind the complexity of the cHL TME and provide translational insights into how to improve therapy in the clinic.

Schlagwörter

Stichwörter der Autor:innen

Classical Hodgkin lymphomaPD-L1T-cellsimmune checkpoint inhibitorsprognostic markerstumour microenvironmenttumour-associated macrophages

Autor:innen und Institutionen

  • Olivia Newton-John Cancer Research & Wellness Centre, Austin Health, 145 Studley Rd., Heidelberg, VIC 3084, Australia.
  • Princess Alexandra Hospital, 199 Ipswich Rd., Woolloongabba, QLD 4102, Australia.
  • Frazer Institute, University of Queensland, St. Lucia, QLD 4072, Australia.
  • School of Public Health & Preventive Medicine, Monash University, 553 St Kilda Rd., Melbourne, VIC 3004, Australia.

Zitieren

APA

Martynchyk, A., Chowdhury, R., Hawkes, E. A., & Keane, C. (2023). Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. Cancers, 15(21), 5217. https://doi.org/10.3390/cancers15215217

Vancouver

Martynchyk A, Chowdhury R, Hawkes EA, Keane C. Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. Cancers. 2023;15(21):5217. doi:10.3390/cancers15215217

BibTeX
@article{Martynchyk2023,
  author = {Martynchyk, Arina and Chowdhury, Rakin and Hawkes, Eliza A and Keane, Colm},
  title = {Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {21},
  pages = {5217},
  doi = {10.3390/cancers15215217}
}
Kostenlos starten →